Kyongbo Pharmaceutical Co., Ltd (KRX:214390)
South Korea
· Delayed Price · Currency is KRW 5,550.00
-30.00 (-0.54%)
At close: Apr 23, 2025, 3:30 PM KST
Kyongbo Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Other Revenue | - | -0 | - | -0 | - | Upgrade
|
| Revenue | 238,556 | 216,357 | 196,265 | 170,660 | 215,285 | Upgrade
|
| Revenue Growth (YoY) | 10.26% | 10.24% | 15.00% | -20.73% | 12.30% | Upgrade
|
| Cost of Revenue | 156,585 | 153,781 | 152,397 | 135,929 | 163,480 | Upgrade
|
| Gross Profit | 81,971 | 62,576 | 43,867 | 34,731 | 51,805 | Upgrade
|
| Selling, General & Admin | 62,961 | 50,588 | 37,580 | 34,398 | 32,632 | Upgrade
|
| Research & Development | 5,312 | 3,654 | 3,077 | 5,053 | 6,238 | Upgrade
|
| Other Operating Expenses | 640.38 | 608.67 | 586.91 | 594.64 | 625.78 | Upgrade
|
| Operating Expenses | 71,517 | 57,032 | 42,475 | 41,356 | 43,144 | Upgrade
|
| Operating Income | 10,454 | 5,545 | 1,393 | -6,625 | 8,661 | Upgrade
|
| Interest Expense | -4,290 | -3,401 | -1,671 | -1,176 | -1,307 | Upgrade
|
| Interest & Investment Income | 70.32 | 143.42 | 14.44 | 25.35 | 73.64 | Upgrade
|
| Earnings From Equity Investments | -1,376 | -376.33 | -463.72 | -85.58 | -220.73 | Upgrade
|
| Currency Exchange Gain (Loss) | -229.62 | 399.22 | -752.16 | 1,402 | -2,221 | Upgrade
|
| Other Non Operating Income (Expenses) | 410.06 | 57.91 | 877.71 | 302.77 | -702.86 | Upgrade
|
| EBT Excluding Unusual Items | 5,039 | 2,368 | -602.16 | -6,156 | 4,283 | Upgrade
|
| Gain (Loss) on Sale of Investments | -130 | -228.13 | -134.66 | -3,836 | 8,072 | Upgrade
|
| Gain (Loss) on Sale of Assets | -6.29 | -11.09 | 121.98 | 58.68 | -592.7 | Upgrade
|
| Asset Writedown | - | 43.11 | - | - | - | Upgrade
|
| Pretax Income | 4,903 | 2,172 | -614.84 | -9,933 | 14,031 | Upgrade
|
| Income Tax Expense | 263.71 | -802.48 | -1,225 | -2,438 | 4,626 | Upgrade
|
| Net Income | 4,639 | 2,974 | 610.59 | -7,495 | 9,404 | Upgrade
|
| Net Income to Common | 4,639 | 2,974 | 610.59 | -7,495 | 9,404 | Upgrade
|
| Net Income Growth | 55.97% | 387.13% | - | - | 77.94% | Upgrade
|
| Shares Outstanding (Basic) | 24 | 24 | 24 | 24 | 24 | Upgrade
|
| Shares Outstanding (Diluted) | 24 | 24 | 24 | 24 | 24 | Upgrade
|
| Shares Change (YoY) | -0.30% | 0.34% | 0.15% | -0.25% | 0.06% | Upgrade
|
| EPS (Basic) | 194.00 | 124.00 | 25.54 | -314.00 | 393.00 | Upgrade
|
| EPS (Diluted) | 194.00 | 124.00 | 25.54 | -314.00 | 393.00 | Upgrade
|
| EPS Growth | 56.45% | 385.50% | - | - | 77.83% | Upgrade
|
| Free Cash Flow | -12,547 | -4,849 | -2,747 | 461.73 | 8,739 | Upgrade
|
| Free Cash Flow Per Share | -524.69 | -202.15 | -114.90 | 19.34 | 365.19 | Upgrade
|
| Gross Margin | 34.36% | 28.92% | 22.35% | 20.35% | 24.06% | Upgrade
|
| Operating Margin | 4.38% | 2.56% | 0.71% | -3.88% | 4.02% | Upgrade
|
| Profit Margin | 1.94% | 1.38% | 0.31% | -4.39% | 4.37% | Upgrade
|
| Free Cash Flow Margin | -5.26% | -2.24% | -1.40% | 0.27% | 4.06% | Upgrade
|
| EBITDA | 22,862 | 17,244 | 13,328 | 6,132 | 21,249 | Upgrade
|
| EBITDA Margin | 9.58% | 7.97% | 6.79% | 3.59% | 9.87% | Upgrade
|
| D&A For EBITDA | 12,408 | 11,699 | 11,936 | 12,757 | 12,588 | Upgrade
|
| EBIT | 10,454 | 5,545 | 1,393 | -6,625 | 8,661 | Upgrade
|
| EBIT Margin | 4.38% | 2.56% | 0.71% | -3.88% | 4.02% | Upgrade
|
| Effective Tax Rate | 5.38% | - | - | - | 32.97% | Upgrade
|
| Advertising Expenses | 3,905 | 3,683 | 1,755 | 4,234 | 6,838 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.